Exciting news in the progress of neflamapimod, a potential treatment for Lewy body dementia. The Innovation Passport award is designed to accelerate time to market and expedite patient access to potentially transformative new investigational medicines.
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) | CervoMed
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP...
ir.cervomed.com